The drug is intended only for adults.
Iriten is administered as an intravenous infusion lasting at least 30 minutes and not more than 90 minutes.
When choosing a dose and mode of administration in each individual case, you should refer to the special literature.
In the monotherapy regime: Iriten is applied at a dose of 350 mg / m2 every 3 weeks.
As part of combined chemotherapy The dose of Iriten is:
- with 5-fluorouracil and calcium folinate at a weekly administration of 80 mg / m2;
- when administered by continuous infusion once every 2 weeks - 180 mg / m2;
- in combination with jet injection of 5-fluorouracil and calcium folinate - 125 mg / m2 weekly.
Doses and regimens for the administration of 5-fluorouracil and calcium folinate are described in detail in the literature.
Iriten should not be administered until the amount of neutrophils in the peripheral blood exceeds 1500 cells / μl, and until such complications as nausea, vomiting and especially diarrhea are completely eliminated. The administration of the drug before the resolution of all side effects can be postponed for 1-2 weeks.
If the development of treatment with expressed inhibition of bone marrow hematopoiesis (the number of neutrophils less than 500 / μl, and / or the number of leukocytes less than 1000 / μl, and / or the number of platelets less than 100,000 / μl), febrile neutropenia (the number of neutrophils 1000 / μL of blood and less in combination with an increase in body temperature of more than 38 ° C), infectious complications, severe diarrhea, or other non-hematologic toxicity of 3-4 degrees, subsequent doses of iritene and, if necessary, 5-fluorouracil should be reduced by 15-20%.
Patients with impaired hepatic function. At a level of bilirubin in the blood serum exceeding the upper limit of the norm no more than 1.5 times, in connection with an increased risk of development of severe neutropenia, blood parameters in the patient should be closely monitored. If the level of bilirubin is increased more than 1.5 times, treatment with Iriten should be stopped.
Patients with impaired renal function. Treatment with iritene is not recommended, as there is no data on the use of irinotecan in this category of patients.
Elderly patients. There are no specific instructions for the use of irinotecan in the elderly.The dose of the drug in each case should be selected with caution.
Instructions for preparing a solution for infusions
The necessary amount of the preparation should be diluted in 250 ml of a 0.5% solution of dextrose or 0.9% sodium chloride solution and the resulting solution is mixed by rotating the vial. Before administration, the solution should be visually inspected for clarity. If a sediment is found, the preparation must be destroyed.
The solution should be used immediately after dilution.
If the dilution is carried out in accordance with aseptic rules (for example, in a laminar air flow installation), the Iritene solution can be used in case of storage at room temperature for 12 hours (including infusion time) and in case of storage at a temperature of 2-8 ° C for 24 hours after opening the vial with concentrate.